Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Flexion Therapeutics
300 TradeCenter, Suite 2460
Woburn, MA 1801
Phone: 781-897-9977
www.flexiontherapeutics.com

Flexion discovers and develops innovative therapeutics for musculoskeletal disorders. In our efforts to provide products with superior efficacy and safety, we are merging novel pharmacology with local, sustained delivery of drug to the site of disease - an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid, is currently being evaluated in a Phase 2b dose ranging study and a pharmacokinetic/pharmacodynamics study. FX007, an intra-articular sustained release TrkA inhibitor is being developed to safely address the intractable pain associated with end-stage osteoarthritis.

Key Contact
Name
Mike Clayman
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
12/04/12 $20,000,000 Series B 5AM Ventures
Novo Ventures
Pfizer Venture Investments
Sofinnova Partners
Versant Ventures
undisclosed


Featured Reading